SOTIO functions as a global biotech organization spearheading the initiatives of PPF Group, one of the primary investment conglomerates in Central and Eastern Europe, to construct a varied pharmaceutical enterprise specialized in oncology. SOTIO is committed to achieving this objective through its proprietary SOTIO® internal exploration and clinical advancement as well as associated services, partnerships with external collaborators, in-licensing arrangements, investments, and acquisitions. The organization is actively progressing novel treatments aimed at addressing cancer and autoimmune ailments. SOTIO has established the essential competencies necessary for scientific research, preclinical and clinical evolution, and commercial strategy.